Test Price
2,800 AED✅ Home Collection Available
Pneumonia Plus Advantage Test (Respiratory Pathogen Panel) in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
The Pneumonia Plus Advantage Test is a comprehensive multiplex PCR assay that rapidly identifies over 20 bacterial, viral, and atypical respiratory pathogens from sputum or bronchoalveolar lavage (BAL) samples. Delivering same-day results with 99.9% diagnostic sensitivity, this molecular panel enables clinicians to initiate targeted antimicrobial therapy within hours, reducing empiric broad-spectrum antibiotic use and improving patient outcomes.
- Price: 2,800 AED
- Turnaround Time: Same day (report by evening)
- Diagnostic Sensitivity: 99.9%
- Pathogen Coverage: 20+ bacterial, viral & atypical targets
- Methodology: Multiplex PCR with LAMP integration
- Collection: Hospital extraction only – sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Test Overview & Methodology
This advanced molecular diagnostic assay employs multiplex PCR technology (BioFire® FilmArray®) integrated with Loop-Mediated Isothermal Amplification (LAMP) to simultaneously detect over 20 respiratory pathogens from a single respiratory specimen. The panel includes Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophila, Mycoplasma pneumoniae, Chlamydia pneumoniae, Influenza A/B, RSV, SARS‑CoV‑2, Adenovirus, Human Metapneumovirus, Parainfluenza 1–4, Rhinovirus, Bordetella pertussis, and Bordetella parapertussis.
| Feature | Pneumonia Plus Advantage Test | Routine Sputum Culture |
|---|---|---|
| Methodology | Multiplex PCR (BioFire® FilmArray®) with LAMP integration | Conventional microbiology culture |
| Turnaround Time | Same day (report by evening) | 48–72 hours |
| Diagnostic Sensitivity | 99.9% | 50–70% |
| Pathogen Coverage | 20+ bacterial, viral & atypical targets | Limited to cultivable bacteria |
| Antibiotic Stewardship | Rapid de‑escalation possible | Delayed results lead to empiric broad‑spectrum use |
Physician Insight & Safety Protocols
“This molecular panel delivers rapid diagnostic clarity for patients presenting with respiratory symptoms. However, laboratory findings must always be interpreted alongside the full clinical history, physical examination, and radiological assessment. I strongly advise patients to review their results with their treating physician to ensure the most appropriate and safe therapeutic decisions are made.”
— Dr. Ajay Singh, General Practitioner, DHA Registration ID: 36234132
Advisory Notes for Patients and Clinicians
Clinical Context Required: A positive result confirms the presence of pathogen nucleic acid and does not differentiate between active infection, colonization, or residual shedding. Correlation with clinical presentation, imaging, and laboratory markers is essential.
Medication Advisory: Do not discontinue, adjust, or initiate any antibiotic, antiviral, or inhaler therapy without direct consultation with your healthcare provider.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Sample Collection
- Grossly blood‑contaminated or insufficient sputum volume (<1 mL)
- Patient unable to produce sputum and declines bronchoscopy for BAL
- Known severe coagulopathy, thrombocytopenia, or hypoxia contraindicating bronchoscopy
- Recent antibiotic therapy – PCR may detect residual DNA; interpret with caution
Seek Emergency Care Immediately If You Experience
- Severe shortness of breath at rest or stridor
- Bluish lips or face (cyanosis)
- Confusion, drowsiness, or loss of consciousness
- High fever (>39°C) not responding to antipyretics
- Chest pain with low oxygen saturation or signs of sepsis
Patient FAQ & Clinical Guidance
1. What pathogens does the Pneumonia Plus Advantage Test detect?
The panel detects over 20 respiratory pathogens including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophila, Mycoplasma pneumoniae, Chlamydia pneumoniae, Influenza A/B, RSV, SARS‑CoV‑2, Adenovirus, Human Metapneumovirus, Parainfluenza 1–4, Rhinovirus, Bordetella pertussis, and Bordetella parapertussis.
2. How is the sample collected and is it painful?
A small volume of sputum (2 mL) is expectorated into a sterile container after deep coughing; this may cause mild discomfort. If a bronchoalveolar lavage (BAL) is required, it is performed under sedation during bronchoscopy and is generally well tolerated. Both procedures are conducted within an accredited hospital facility.
3. How soon will I receive my results?
Results are released the same day if the sample is received by 1:00 PM. You will receive a detailed electronic report and can access a post‑test tele‑consultation with a clinician to discuss the findings and next steps.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework: All testing procedures at DNA Labs UAE adhere to the highest standards of patient safety and data protection under UAE law. Patient data is handled in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent protocols are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
Quality Certification: DNA Labs UAE is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139), ensuring internationally recognized quality management standards across all laboratory operations.
Clinical & Logistical Metadata
| Test Name | Pneumonia Plus Advantage Test (Respiratory Pathogen Panel) |
| Price (AED) | 2,800 AED |
| Turnaround Time | Same day (report by evening) |
| Sample Type / Matrix | Sputum or Bronchoalveolar Lavage (BAL) – Hospital extraction only; sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | Multiplex PCR (BioFire® FilmArray®) with LAMP integration |
| ICD-10-CM Code | J18.9 (Pneumonia, unspecified organism) |
| LOINC Code | 103271-2 (Respiratory pathogens DNA and RNA panel – Respiratory specimen by NAA with probe detection) |
| DHA Facility License & Laboratory Address | DHA Facility License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians